Tadalafil Tablet, Film Coated
Product Images NDC 71335-1255

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351255)

Tadalafil 20 mg tablet label, film-coated oral dosage form, packaged by Bryant Ranch Prepack, Burbank, CA. The label references comparison to Cialis 20 mg tablet by Sun Pharmaceutical Industries Inc., includes storage instructions at 20°-25°C (68°-77°F), and a caution to keep drugs out of children's reach. The National Drug Code 71335-1255 is shown.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

A set of four line graphs displaying blood pressure changes over time in hours. The graphs show differences in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, comparing tadalafil treatment to placebo. Each graph includes error bars indicating variability around the measurements.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

Two line graphs depicting changes in systolic blood pressure (mmHg) over 24 hours post-dose. The top graph shows standing systolic BP, and the bottom graph shows supine systolic BP. Each compares Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg over time.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

A line graph showing changes in systolic blood pressure (mmHg) over a 12-hour period after administration of 20 mg tadalafil or placebo, each combined with 8 mg doxazosin dosed at 08:00. Four data sets are plotted, differentiating between dosing times at 08:00 and 20:00 for tadalafil and placebo combined with doxazosin. The y-axis displays systolic BP changes from -20 to +20 mmHg, while the x-axis shows time after administration from 0 to 12 hours.*

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing conditions: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph includes error bars and illustrates the pharmacokinetic profile of tadalafil across 120 hours.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

Line graph depicting the change from baseline in IPSS total score over a 12-week treatment period. It compares Tadalafil 5 mg and placebo, showing a greater reduction in IPSS score with Tadalafil. The x-axis represents treatment duration in weeks, and the y-axis shows the change in score from 0 to -6.*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment duration between Tadalafil 5 mg and placebo groups. The y-axis shows change from baseline in IPSS total score, and the x-axis indicates treatment duration in weeks. Tadalafil shows a greater decrease in score compared to placebo, with statistically significant differences marked at weeks 4 and 12 (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks for Tadalafil 5 mg versus Placebo. The x-axis represents treatment duration in weeks (0, 2, 4, 8, 12), and the y-axis shows change from baseline in IPSS Total Score, ranging from 0 to -6. Tadalafil shows a greater decrease over time compared to placebo, with statistical significance noted at 12 weeks (p<0.01).*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

Chemical structure of Tadalafil showing the intricate arrangement of rings and functional groups characteristic of this pharmaceutical compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.